Concurrent lung infections in patients with hematological malignancies and invasive pulmonary aspergillosis: How firm is the Aspergillus diagnosis?

Journal of Infection

Volumn 65, Issue 3, 2012, Pages 262-268

  Georgiadou, Sarah P ^a   Kontoyiannis, Dimitrios P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aspergillus; Coinfection; Hematologic; Immunocompromised; Pulmonary

Indexed keywords

BETA LACTAM ANTIBIOTIC;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS FLAVUS; ASPERGILLUS FUMIGATUS; BACTERIAL INFECTION; CANCER CENTER; CHILD; CONCURRENT INFECTION; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOCOMPROMISED PATIENT; LUNG ASPERGILLOSIS; LUNG INFECTION; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; NEUTROPENIA; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADULT; AGED; ANTIFUNGAL AGENTS; CHI-SQUARE DISTRIBUTION; COINFECTION; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84864538954     PISSN: 01634453     EISSN: 15322742     Source Type: Journal    
DOI: 10.1016/j.jinf.2012.05.001     Document Type: Article

References (51)

1. Chamilos G., Luna M., Lewis R.E., Bodey G.P., Chemaly R., Tarrand J.J., et al. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: an autopsy study over a 15-year period (1989-2003). Haematologica 2006, 91:986-989.
2. Abbasi S., Shenep J.L., Hughes W.T., Flynn P.M. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999, 29:1210-1219.
3. Ben-Ami R., Lewis R.E., Raad, Kontoyiannis D.P. Phaeohyphomycosis in a tertiary care cancer center. Clin Infect Dis 2009, 48:1033-1041.
4. Burghi G., Lemiale V., Seguin A., Lambert J., Lacroix C., Canet E., et al. Outcomes of mechanically ventilated hematology patients with invasive pulmonary aspergillosis. Intensive Care Med 2011, 37:1605-1612.
5. Burgos A., Zaoutis T.E., Dvorak C.C., Hoffman J.A., Knapp K.M., Nania J.J., et al. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008, 121:e1286-e1294.
6. Campo M., Lewis R.E., Kontoyiannis D.P. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. J Infect 2010, 60:331-337.
7. Chamilos G., Lewis R.E., Kontoyiannis D.P. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008, 47:503-509.
8. Crassard N., Hadden H., Piens M.A., Pondarré C., Hadden R., Galambrun C., et al. Invasive aspergillosis in a paediatric haematology department: a 15-year review. Mycoses 2008, 51:109-116.
9. Jandrlic M., Kalenic S., Labar B., Nemet D., Jakić-Razumović J., Mrsić M., et al. An autopsy study of systemic fungal infections in patients with hematologic malignancies. Eur J Clin Microbiol Infect Dis 1995, 14:768-774.
10. Kontoyiannis D.P., Wessel V.C., Bodey G.P., Rolston K.V. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin Infect Dis 2000, 30:851-856.
11. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
12. Larone D.H. Medically important fungi 2002, ASM Press, Washington, D.C. 4th ed.
13. Rolston K.V., Bodey G.P., Safdar A. Polymicrobial infection in patients with cancer: an underappreciated and underreported entity. Clin Infect Dis 2007, 45:228-233.
14. Alangaden G.J., Wahiduzzaman M., Chandrasekar P.H. Aspergillosis: the most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 2002, 35:659-664.
15. Jacobson K.L., Miceli M.H., Tarrand J.J., Kontoyiannis D.P. Legionella pneumonia in cancer patients. Medicine (Baltimore) 2008, 87:152-159.
16. Torres H.A., Reddy B.T., Raad, Tarrand J., Bodey G.P., Hanna H.A., et al. Nocardiosis in cancer patients. Medicine (Baltimore) 2002, 81:388-397.
17. Jadad A.R., To M.J., Emara M., Jones J. Consideration of multiple chronic diseases in randomized controlled trials. JAMA 2011, 306:2670-2672.
18. Caillot D., Thiebaut A., Herbrecht R., de Botton S., Pigneux A., Bernard F., et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007, 110:2740-2746.
19. Cornely O.A., Maertens J., Bresnik M., Ebrahimi R., Ullmann A.J., Bouza E., et al. Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 2007, 44:1289-1297.
20. Herbrecht R., Denning D.W., Patterson T.F., Bennett J.E., Greene R.E., Oestmann J.W., et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002, 347:408-415.
21. Hachem R.Y., Langston A.A., Graybill J.R., Perfect J.R., Pedicone L.D., Patino H., et al. Posaconazole as salvage treatment of invasive fungal infections in patients with underlying renal impairment. J Antimicrob Chemother 2008, 62:1386-1391.
22. Kartsonis N.A., Saah A.J., Joy Lipka C., Taylor A.F., Sable C.A. Salvage therapy with caspofungin for invasive aspergillosis: results from the caspofungin compassionate use study. J Infect 2005, 50:196-205.
23. Maertens J., Raad I., Petrikkos G., Boogaerts M., Selleslag D., Petersen F.B., et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004, 39:1563-1571.
24. Mihu C.N., Kassis C., Ramos E.R., Jiang Y., Hachem R.Y., Raad Does combination of lipid formulation of amphotericin B and echinocandins improve outcome of invasive aspergillosis in hematological malignancy patients?. Cancer 2010, 116:5290-5296.
25. Raad, Hanna H.A., Boktour M., Jiang Y., Torres H.A., Afif C., et al. Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. Leukemia 2008, 22:496-503.
26. Walsh T.J., Raad I., Patterson T.F., Chandrasekar P., Donowitz G.R., Graybill R., et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007, 44:2-12.
27. Denning D.W., Ribaud P., Milpied N., Caillot D., Herbrecht R., Thiel E., et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002, 34:563-571.
28. Hachem R.Y., Boktour M.R., Hanna H.A., Husni R.N., Torres H.A., Afif C., et al. Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. Cancer 2008, 112:1282-1287.
29. Martino R., Cortes M., Subira M., Parody R., Moreno E., Sierra J. Efficacy and toxicity of intermediate-dose amphotericin B lipid complex as a primary or salvage treatment of fungal infections in patients with hematological malignancies. Leuk Lymphoma 2005, 46:1429-1435.
30. Nouer S.A., Nucci M., Kumar N.S., Grazziutti M., Barlogie B., Anaissie E. Earlier response assessment in invasive aspergillosis based on the kinetics of serum Aspergillus galactomannan: proposal for a new definition. Clin Infect Dis 2011, 53:671-676.
31. Chandrasekar P. Diagnostic challenges and recent advances in the early management of invasive fungal infections. Eur J Haematol 2010, 84:281-290.
32. Cuenca-Estrella M., Bassetti M., Lass-Florl C., Racil Z., Richardson M., Rogers T.R. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011, 66(Suppl. 1):i15-i24.
33. Georgiadou S.P., Sipsas N.V., Marom E.M., Kontoyiannis D.P. The diagnostic value of halo and reversed halo signs for invasive mold infections in compromised hosts. Clin Infect Dis 2011, 52:1144-1155.
34. Park S.Y., Lim C., Lee S.O., Choi S.H., Kim Y.S., Woo J.H., et al. Computed tomography findings in invasive pulmonary aspergillosis in non-neutropenic transplant recipients and neutropenic patients, and their prognostic value. J Infect 2011, 63:447-456.
35. Aquino V.R., Goldani L.Z., Pasqualotto A.C. Update on the contribution of galactomannan for the diagnosis of invasive aspergillosis. Mycopathologia 2007, 163:191-202.
36. Boonsarngsuk V., Niyompattama A., Teosirimongkol C., Sriwanichrak K. False-positive serum and bronchoalveolar lavage Aspergillus galactomannan assays caused by different antibiotics. Scand J Infect Dis 2010, 42:461-468.
37. Albert O., Toubas D., Strady C., Cousson J., Delmas C., Vernet V., et al. Reactivity of (1→3)-beta-d-glucan assay in bacterial bloodstream infections. Eur J Clin Microbiol Infect Dis 2011, 30:1453-1460.
38. Racil Z., Kocmanova I., Lengerova M., Weinbergerova B., Buresova L., Toskova M., et al. Difficulties in using 1,3-{beta}-d-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies - high frequency of false-positive results and their analysis. J Med Microbiol 2010, 59:1016-1022.
39. Mennink-Kersten M.A., Ruegebrink D., Verweij P.E. Pseudomonas aeruginosa as a cause of 1,3-beta-d-glucan assay reactivity. Clin Infect Dis 2008, 46:1930-1931.
40. Cummings J.R., Jamison G.R., Boudreaux J.W., Howles M.J., Walsh T.J., Hayden R.T. Cross-reactivity of non-Aspergillus fungal species in the Aspergillus galactomannan enzyme immunoassay. Diagn Microbiol Infect Dis 2007, 59:113-115.
41. Tortorano A.M., Esposto M.C., Prigitano A., Grancini A., Ossi C., Cavanna C., et al. Cross-reactivity of Fusarium spp. in the Aspergillus galactomannan enzyme linked immunosorbent assay. J Clin Microbiol 2012, 50:1051-1053.
42. Bissinger A.L., Einsele H., Hamprecht K., Schumacher U., Kandolf R., Loeffler J., et al. Infectious pulmonary complications after stem cell transplantation or chemotherapy: diagnostic yield of bronchoalveolar lavage. Diagn Microbiol Infect Dis 2005, 52:275-280.
43. Stanzani M., Battista G., Sassi C., Lewis R.E., Tolomelli G., Clissa C., et al. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clin Infect Dis 2012, 54:610-616.
44. Zaas A.K., Aziz H., Lucas J., Perfect J.R., Ginsburg G.S. Blood gene expression signatures predict invasive candidiasis. Sci Transl Med 2010, 2:21ra17.
45. Gonzales D.A., De Torre C., Wang H., Devor C.B., Munson P.J., Ying S.X., et al. Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia. Proteomics 2010, 10:4270-4280.
46. Kontoyiannis D.P. Are serum cytokines sensitive and specific enough to prognosticate in aspergillosis?. J Infect Dis 2011, 203:1503. Author reply 1504.
47. Peleg A.Y., Hogan D.A., Mylonakis E. Medically important bacterial-fungal interactions. Nat Rev Microbiol 2010, 8:340-349.
48. Bakaletz L.O. Developing animal models for polymicrobial diseases. Nat Rev Microbiol 2004, 2:552-568.
49. Diaz M.H., Shaver C.M., King J.D., Musunuri S., Kazzaz J.A., Hauser A.R. Pseudomonas aeruginosa induces localized immunosuppression during pneumonia. Infect Immun 2008, 76:4414-4421.
50. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
51. Peters B.M., Jabra-Rizk M.A., O'May G.A., Costerton J.W., Shirtliff M.E. Polymicrobial interactions: impact on pathogenesis and human disease. Clin Microbiol Rev 2012, 25:193-213.